InspireMD Aktie

View in Terminal

Loading quotes...

Forecast

The analysts' average price target is €3.13 (+682.50%). The median is €3.13 (+682.50%).

Buy	6
Hold	1
Sell	0

News Go to news feed

There is currently no news available for this company. We are working on adding more providers to change this.

Financials

In the last quarter, InspireMD Aktie had revenue of €1.55M and net profit of -€12.55M

(EUR)	June 2026	YoY
Revenue	1.55M	2.87%
Gross profit	-678.19K	355.38%
Net profit	-12.55M	12.49%
EBITDA	-12.41M	13.31%

Fundamentals

Metric	Value
Market capitalization	€19.38M
Number of shares	46.49M
52-week high/low	€2.16 - €0.38
Dividends	No
Beta	0.83
P/E ratio	-0.94
PEG ratio	-0.02
P/B ratio	1.09
P/S ratio	2.00

Company profile

InspireMD, Inc., a medical device company, focuses on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system for use in carotid artery applications; and MGuard Prime embolic protection systems for use in patients with acute coronary syndromes, notably acute myocardial infarction, and saphenous vein graft coronary interventions, as well as bypass surgery. It is also developing PVGuard, a MicroNet mesh sleeve and self-expandable stent for use in peripheral vascular applications. The company sells its products through local distributors. InspireMD, Inc. was founded in 2005 and is headquartered in Tel Aviv-Yafo, Israel.